Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study

This publication has 19 references indexed in Scilit:

• Current status and progress of prepandemic and pandemic influenza vaccine development
  Expert Review of Vaccines, 2009
• MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
  PLOS ONE, 2009
• Antigenically Distinct MF59-Adjuvanted Vaccine to Boost Immunity to H5N1
  New England Journal of Medicine, 2008
• An Adjuvanted, Low‐Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross‐Reactive Immune Responses in Healthy Adults
  The Journal of Infectious Diseases, 2008
• Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial
  Vaccine, 2008
• Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults
  The Journal of Infectious Diseases, 2008
• Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine
  PLOS ONE, 2008
• Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial
  The Lancet, 2007
• Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial
  The Lancet, 2006
• Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine
  New England Journal of Medicine, 2006